These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 39159629)

  • 1. Prevalence of mutations associated with artemisinin partial resistance and sulfadoxine-pyrimethamine resistance in 13 regions in Tanzania in 2021: a cross-sectional survey.
    Juliano JJ; Giesbrecht DJ; Simkin A; Fola AA; Lyimo BM; Pereus D; Bakari C; Madebe RA; Seth MD; Mandara CI; Popkin-Hall ZR; Moshi R; Mbwambo RB; Niaré K; MacInnis B; Francis F; Mbwambo D; Garimo I; Chacky F; Aaron S; Lusasi A; Molteni F; Njau RJA; Nhiga SL; Mohamed A; Bailey JA; Ishengoma DS
    Lancet Microbe; 2024 Oct; 5(10):100920. PubMed ID: 39159629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.
    Kateera F; Nsobya SL; Tukwasibwe S; Hakizimana E; Mutesa L; Mens PF; Grobusch MP; van Vugt M; Kumar N
    Acta Trop; 2016 Dec; 164():329-336. PubMed ID: 27647575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania.
    Juliano JJ; Giesbrecht DJ; Simkin A; Fola AA; Lyimo BM; Pereus D; Bakari C; Madebe RA; Seth MD; Mandara CI; Popkin-Hall ZR; Moshi R; Mbwambo RB; Niaré K; MacInnis B; Francis F; Mbwambo D; Garimo I; Chacky F; Aaron S; Lusasi A; Molteni F; Njau RJA; Lazaro S; Mohamed A; Bailey JA; Ishengoma DS
    medRxiv; 2023 Nov; ():. PubMed ID: 37986920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of artemisinin partial resistance mutations and lack of histidine rich protein-2 and -3 deletions in Plasmodium falciparum infections from Rukara, Rwanda.
    Schreidah C; Giesbrecht D; Gashema P; Young NW; Munyaneza T; Muvunyi CM; Thwai K; Mazarati JB; Bailey JA; Juliano JJ; Karema C
    Malar J; 2024 May; 23(1):150. PubMed ID: 38755607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased prevalence of pfdhfr and pfdhps mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Jazan Region, Southwestern Saudi Arabia: important implications for malaria treatment policy.
    Madkhali AM; Al-Mekhlafi HM; Atroosh WM; Ghzwani AH; Zain KA; Abdulhaq AA; Ghailan KY; Anwar AA; Eisa ZM
    Malar J; 2020 Dec; 19(1):446. PubMed ID: 33267841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective analysis of
    Ogwang R; Osoti V; Wamae K; Ndwiga L; Muteru K; Ningwa A; Tuju J; Kinyanjui S; Osier F; Marsh K; Bejon P; Idro R; Ochola-Oyier LI
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0157623. PubMed ID: 39136465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance for sulfadoxine-pyrimethamine resistant malaria parasites in the Lake and Southern Zones, Tanzania, using pooling and next-generation sequencing.
    Ngondi JM; Ishengoma DS; Doctor SM; Thwai KL; Keeler C; Mkude S; Munishi OM; Willilo RA; Lalji S; Kaspar N; Kitojo C; Paxton LA; Hathaway NJ; Bailey JA; Juliano JJ; Meshnick SR; Gutman J
    Malar J; 2017 Jun; 16(1):236. PubMed ID: 28583119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014.
    Mishra S; Bharti PK; Shukla MM; Ali NA; Kashyotia SS; Kumar A; Dhariwal AC; Singh N
    Pathog Glob Health; 2017 Jun; 111(4):186-194. PubMed ID: 28549390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine-pyrimethamine in Tanzania.
    Kavishe RA; Kaaya RD; Nag S; Krogsgaard C; Notland JG; Kavishe AA; Ishengoma D; Roper C; Alifrangis M
    Malar J; 2016 Jun; 15():335. PubMed ID: 27339129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine-tolerance molecular markers following 18 years of artemisinin-based combination therapy use in Mpumalanga Province, South Africa (2001-2018).
    Raman J; Kagoro FM; Mabuza A; Malatje G; Reid A; Frean J; Barnes KI
    Malar J; 2019 Aug; 18(1):280. PubMed ID: 31438951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance.
    Ishengoma DS; Mandara CI; Bakari C; Fola AA; Madebe RA; Seth MD; Francis F; Buguzi CC; Moshi R; Garimo I; Lazaro S; Lusasi A; Aaron S; Chacky F; Mohamed A; Njau RJA; Kitau J; Rasmussen C; Bailey JA; Juliano JJ; Warsame M
    Lancet Infect Dis; 2024 Aug; ():. PubMed ID: 39159633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Evidence for
    Wedam J; Tacoli C; Gai PP; Siegert K; Kulkarni SS; Rasalkar R; Boloor A; Jain A; Mahabala C; Baliga S; Shenoy D; Devi R; Gai P; Mockenhaupt FP
    Am J Trop Med Hyg; 2018 Dec; 99(6):1508-1510. PubMed ID: 30398146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
    Awab GR; Imwong M; Pukrittayakamee S; Alim F; Hanpithakpong W; Tarning J; Dondorp AM; Day NP; White NJ; Woodrow CJ
    Malar J; 2016 Feb; 15():121. PubMed ID: 26917051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytes.
    Atroosh WM; Al-Mekhlafi HM; Snounou G; Al-Jasari A; Sady H; Nasr NA; Lau YL; Surin J
    Malar J; 2016 May; 15(1):295. PubMed ID: 27234587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence and risk of malaria among asymptomatic individuals from villages with high prevalence of artemisinin partial resistance in Kyerwa district of Kagera region, north-western Tanzania.
    Mandai SS; Francis F; Challe DP; Seth MD; Madebe RA; Petro DA; Budodo R; Kisambale AJ; Chacha GA; Moshi R; Mbwambo RB; Pereus D; Bakari C; Aaron S; Mbwambo D; Lusasi A; Kajange S; Lazaro S; Kapologwe N; Mandara CI; Ishengoma DS
    Malar J; 2024 Jun; 23(1):197. PubMed ID: 38926854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania.
    Bwire GM; Ngasala B; Mikomangwa WP; Kilonzi M; Kamuhabwa AAR
    Sci Rep; 2020 Feb; 10(1):3500. PubMed ID: 32103124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable high frequencies of sulfadoxine-pyrimethamine resistance associated mutations and absence of K13 mutations in Plasmodium falciparum 3 and 4 years after the introduction of artesunate plus sulfadoxine-pyrimethamine in Ujjain, Madhya Pradesh, India.
    Pathak A; Mårtensson A; Gawariker S; Sharma A; Diwan V; Purohit M; Ursing J
    Malar J; 2020 Aug; 19(1):290. PubMed ID: 32795288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmodium falciparum Genetic Diversity in Continental Equatorial Guinea before and after Introduction of Artemisinin-Based Combination Therapy.
    Guerra M; Neres R; Salgueiro P; Mendes C; Ndong-Mabale N; Berzosa P; de Sousa B; Arez AP
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevailing Plasmodium falciparum dihydrofolate reductase 108-asparagine in Hodeidah, Yemen: a questionable sulfadoxine-pyrimethamine partner within the artemisinin-based combination therapy.
    Abdul-Ghani R; Farag HF; Allam AF; Shawky SM
    Acta Trop; 2014 Apr; 132():39-44. PubMed ID: 24406851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of molecular markers of sulfadoxine-pyrimethamine and artemisinin resistance in Plasmodium falciparum from Pakistan.
    Yaqoob A; Khattak AA; Nadeem MF; Fatima H; Mbambo G; Ouattara A; Adams M; Zeeshan N; Takala-Harrison S
    Malar J; 2018 Dec; 17(1):471. PubMed ID: 30558587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.